China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

According to public statistics, the transaction value of the global TOP10 healthcare M&A deals in 2021 will all be more than $3 billion, of which Thermo Fisher’s acquisition of PPD for $17.4 billion ranks first

Illumina announced a bevy of new business partnerships, products, and technology advances Monday at the 2022 JP Morgan Healthcare Conference, held virtually this week.

SQI Diagnostics said on Monday that it has signed a definitive agreement to acquire Precision Biomonitoring's SARS-CoV-2 testing business and related molecular diagnostic technology for $6.825 million in cash and stock.

A variety of diagnostic companies, including Danaher, PerkinElmer, Cue Health, T2 Biosystems, SomaLogic, and Fluidigm, announced preliminary earnings results for the fourth quarter and full year 2021 on Tuesday.

Due to the substantial increase in overseas sales of the COVID-19 Test kit launched in 2021, many listed IVD companies estimate that their profits will surge in 2021.

Scientists have just slotted into place a big piece of the puzzle that explains how our blood cells mount their first line of defence against viruses. They hope this discovery will help them one day better control the response to either boost it or calm it down as appropriate.

Multiple diagnostic firms released preliminary earnings results for the fourth quarter and full year of 2021 on Monday, including CareDx, Castle Biosciences, Lucira Health, OpGen, Adaptive Biotechnologies, and Sema4.

Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash.

Quidel is set to beat analyst expectations in the fourth quarter on the back of rising demand for COVID-19 tests that brought revenues up to around $635 million.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 25, 2021.